Clinical Trials Logo

Clinical Trial Summary

Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible, and then getting rid of it. This is called the 'shock and kill' approach. So far, the drugs tested can find the virus, but they don't get rid of it completely. That's why there need to be new drugs that can do this more effectively. The Erasmus MC HIV Eradication Group (EHEG) has been testing new drugs in the lab and found a drug called topiramate can wake up the virus without harming the cells. The aim of this study is to test topiramate in people living with HIV. Most of the people that participate in HIV cure studies are men, even though most people living with HIV around the world are women. Previous research has shown that men and women might respond differently to these treatments. So, in this study, topiramate will be investigated in both men and women. This could help us find a cure that works for everyone.


Clinical Trial Description

Despite antiretroviral therapy (ART), an infection with the human immunodeficiency virus 1 (HIV-1) is still a lifelong disease because of the latent HIV reservoir. This reservoir consists of a pool of long-lived cells harbouring an integrated copy of the HIV provirus in its genome. One approach to curing HIV centres on reversing viral latency, combined with the subsequent elimination of the virus from this reservoir specifically, all while safeguarding other cells through the use of ART. This approach is colloquially known as 'shock and kill'. The limited number of latency reversing agents (LRAs) that have been studied were effective at reactivating the latent reservoir, but do not result in significant reservoir reduction (Debrabander, 2023). Investigating novel LRAs is, therefore, necessary to identify more potent ways of HIV reactivation, with the ultimate goal of reservoir depletion i.e. a functional HIV cure. The Erasmus MC HIV Eradication group has set up a translational trial platform, where successfully study the effects of novel LRAs from bench to bedside. One example is the discovery of small molecule inhibitors of BAF, which reverse HIV-1 latency, to a clinical trial investigating pyrimethamine in people living with HIV (PLWH) (Stoszko, 2016; Prins, 2023). A new promising drug target that was identified in EHEG is the glutamate receptor, ionotropic kainate 5 (GRIK5); a host factor involved in HIV latency (Roling, 2021). The registered drug topiramate was identified as a potential GRIK5 inhibitor. Further ex vivo testing confirmed HIV latency reversal of topiramate at therapeutic levels without inducing cytotoxic effects. This opens new opportunities for HIV cure research. A further knowledge gap to be explored is the influence of sex in HIV latency reversal. Typically, either by design or recruitment, male participants have been vastly overrepresented in HIV cure research (Barr, 2020). This is despite previous research showing significant difference in HIV latency reversal in women (Rao, 2022), and the importance of sex in pharmacodynamics being increasingly recognised (Gandhi, 2004; Mauvais-Jarvis, 2021). As the majority of PLWH worldwide are women and their numbers are expected to grow, studies on any potential cure strategy that provide an evidence base for their use in women increase clinical impact (UNAIDS, 2023). Therefore, the aim of this study is to examine the effect and safety of topiramate as an LRA in both men and women. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06282783
Study type Interventional
Source Erasmus Medical Center
Contact
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date September 2024
Completion date August 2025

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2